ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

AJU Pharm and Bial - Portela C side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

AJU PharmBial - Portela C
studies on the registry21139
open to participants now71
phase 3 studies under way10
reach primary completion within a year20
programswith a study of their own in two years42

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseAJU PharmBial - Portela C
Phase 1

AJU Pharm: 3 of its 4 programs at phase 1

  1. Comparator 1phase 1
  2. Comparator 2phase 1
  3. R713Rphase 1
75%

Bial - Portela C: 1 of its 2 programs at phase 1

  1. sutezolidphase 1
50%
Phase 200%

Bial - Portela C: 1 of its 2 programs at phase 2

  1. zamicastatphase 2
50%
Phase 300%00%
Approved, new studies

AJU Pharm: 1 of its 4 programs at approved, new studies

  1. B55R1 and B55R2approved, new study
25%
00%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
AJU Pharm0 readouts · 0 phase 3············
Bial - Portela C0 readouts · 0 phase 3············
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 22, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

AJU Pharm

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Bial - Portela C

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Where they overlap

Conditions where at least two of them have programs: 1 in all. A program counts in each condition its studies name most.

ConditionAJU PharmBial - Portela C
Diabetes Mellitus, Type 2both · compare here

AJU Pharm in Diabetes Mellitus, Type 2: 2 programs

  1. Comparator 1phase 1
  2. Comparator 2phase 1

Their studies: AJU Pharm’s studies of Diabetes Mellitus, Type 2 in search

Bial - Portela C in Diabetes Mellitus, Type 2: 1 program

  1. sutezolidphase 1

Their studies: Bial - Portela C’s studies of Diabetes Mellitus, Type 2 in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

No gene two of them both target, among the programs whose target is known.

A target, or a pathogen for a vaccine, known for: AJU Pharm 0 of 4 · Bial - Portela C 2 of 2 programs (1 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.